TiGenix
TiGenix (Euronext: TIG) is a European cell therapy company with a proprietary validated allogeneic expanded adipose-derived stem cell (eASC) platform technology for the treatment of autoimmune and inflammatory diseases, and a commercialised product. Its corporate headquarters are in Leuven, Belgium, and it has operations in Madrid, Spain. TiGenix was founded in 2000 by Prof. Dr. Frank P. Luyten and Gil Beyen as a spin-off from the Katholieke Universiteit Leuven and the Ghent University.
Link from a Wikipage to another Wikipage
primaryTopic
TiGenix
TiGenix (Euronext: TIG) is a European cell therapy company with a proprietary validated allogeneic expanded adipose-derived stem cell (eASC) platform technology for the treatment of autoimmune and inflammatory diseases, and a commercialised product. Its corporate headquarters are in Leuven, Belgium, and it has operations in Madrid, Spain. TiGenix was founded in 2000 by Prof. Dr. Frank P. Luyten and Gil Beyen as a spin-off from the Katholieke Universiteit Leuven and the Ghent University.
has abstract
TiGenix (Euronext: TIG) is a E ...... orms of allogeneic stem cells.
@en
founding year
industry
key person
number of employees
type
Link from a Wikipage to an external page
Wikipage page ID
19,073,358
page length (characters) of wiki page
Wikipage revision ID
1,022,070,337
Link from a Wikipage to another Wikipage
foundation
homepage
industry
key people
Eduardo Bravo, CEO
@en
Location
Leuven, Belgium
@en
name
TiGenix NV
@en
num employees
type
Public
@en
wikiPageUsesTemplate
subject
hypernym
comment
TiGenix (Euronext: TIG) is a E ...... uven and the Ghent University.
@en
label
TiGenix
@en
closeMatch
wasDerivedFrom
homepage
isPrimaryTopicOf
name
TiGenix NV
@en